Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165087 · ClinicalTrials.gov registry record · Phase 3
Treatment of Childhood Acute Lymphoblastic Leukemia
A Phase 3 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 491
- Enrollment target
NCT00165087 is a Phase 3 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 491 participants.
The verdict
NCT00165087, a Phase 3 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 491 participants
- Enrollment target
Study Summary
The purpose of this study is to reduce the side-effects and discomfort of anti-leukemia therapy, to attain long-term control of the disease and to hopefully eradicate it.
Interventions
- DRUG doxorubicin
- DRUG asparaginase (E. Coli)
- DRUG asparaginase (Erwina)
- DRUG dexrazoxane
- PROCEDURE cranial radiation (once daily fractionation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 491 participants |
| Start Date | 1996-01 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165087
The ClinicalTrials.gov registry entry for NCT00165087 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 491 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which doxorubicin is the first listed.
NCT00165087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00165087 about?
NCT00165087 is a clinical study titled "Treatment of Childhood Acute Lymphoblastic Leukemia". The purpose of this study is to reduce the side-effects and discomfort of anti-leukemia therapy, to attain long-term control of the disease and to hopefully eradicate it.
What is the current status of trial NCT00165087?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 491 participants. The study started on 1996-01. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00165087?
The interventions under investigation include: doxorubicin (DRUG), asparaginase (E. Coli) (DRUG), asparaginase (Erwina) (DRUG), dexrazoxane (DRUG), cranial radiation (once daily fractionation) (PROCEDURE).
Who is sponsoring clinical trial NCT00165087?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.